This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
Avadel (AVDL) Is Up 21.13% in One Week: What You Should Know
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019
by Sanghamitra Saha
Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for December 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 9th
Will Avadel Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
by Zacks Equity Research
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Do Options Traders Know Something About Avadel Pharmaceuticals (AVDL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
by Zacks Equity Research
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
Avadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3%
by Zacks Equity Research
Avadel Pharmaceuticals plc (AVDL) shares rose over 5% in the last trading session.
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include FLML, CPHD and EFOI.